Yanneth Moya-Olave

Dr. Yanneth Moya-Olave

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2019 in Schizophrenia Research and Treatment
Verified
Journal Article
Open access
PDF file
ACAlvaro Cavieres
Alvaro Cavieres
CCCarolina Andrea Campos
Carolina Andrea Campos
YMYanneth Moya-Olave
Yanneth Moya-Olave
RMRocío Maldonado
Rocío Maldonado
RGRené González-Vargas
René González-Vargas
PMPablo R Moya
Pablo R Moya
Alterations in neuroinflammatory processes have been suggested to contribute to the development of Schizophrenia (SZ); one component of the inflammatory system that has been linked to this disorder is interleukin-6 (IL-6). The minor allele of rs2228145, a functional polymorphism in the IL-6 receptor gene, has been associated to elevated IL-6 plasma levels and increased inflammatory activity, making it an interesting candidate to study as a possible factor underlying clinical heterogeneity in SZ. We studied a sample of 100 patients undergoing treatment with clozapine. Their symptoms were quantified by Brief Psychotic Rating Scale; those with the lowest scores (“remitted”) were compared with the highest (“clozapine treatment resistant”). We determined allelic frequencies for rs2228145 and IL-6 plasma levels. Our results do not support a role of IL-6 in response to treatment with clozapine. Further studies accounting for potential confounding factors are necessary.

1 August 2012 in Revista chilena de infectología
Verified
Journal Article
Open access
PDF file
YMYanneth Moya-Olave
Yanneth Moya-Olave
FBFernando Bernal
Fernando Bernal
EREliana Rojas
Eliana Rojas
EBElizabeth Barthel
Elizabeth Barthel
Adherence to antiretroviral therapy is key contributor to decreasing morbidity and mortality from HIV/ AIDS infection. However, it is affected by treatment-related factors including the multiple adverse reactions and interactions arising from chronic polypharmacy. In order to determine drug-related problems, 66 outpatients from Hospital Carlos Van Buren on antiretroviral therapy were monitored. 100 % had medication-related problems and 46.1% of those problems were related to the safety of the therapy. Hypertriglyceridemia associated to the combined use of both nucleoside reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor was the most frequent adverse reaction. Results show that pharmacological monitoring of patients on antiretroviral treatment is necessary for the early identification of drug-related problems and for the proposal of alternatives that promote therapeutic safety and efficacy.